BR112014018850A8 - Composição e sua utilização no tratamento de rágades anais - Google Patents

Composição e sua utilização no tratamento de rágades anais

Info

Publication number
BR112014018850A8
BR112014018850A8 BR112014018850A BR112014018850A BR112014018850A8 BR 112014018850 A8 BR112014018850 A8 BR 112014018850A8 BR 112014018850 A BR112014018850 A BR 112014018850A BR 112014018850 A BR112014018850 A BR 112014018850A BR 112014018850 A8 BR112014018850 A8 BR 112014018850A8
Authority
BR
Brazil
Prior art keywords
composition
anal
treatment
ragadis
present
Prior art date
Application number
BR112014018850A
Other languages
English (en)
Other versions
BR112014018850A2 (pt
Inventor
Bastia Filippo
Saccomanno Maurizio
Original Assignee
Thd Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46001672&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014018850(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Thd Spa filed Critical Thd Spa
Publication of BR112014018850A2 publication Critical patent/BR112014018850A2/pt
Publication of BR112014018850A8 publication Critical patent/BR112014018850A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

COMPOSIÇÃO E SUA UTILIZAÇÃO NO TRATAMENTO DE RÁGADES ANAIS A presente invenção refere-se a uma composição, que compreende, pelo menos, um extrato de proteína de hibisco e/ou, pelo menos, um beta glucano ou seu sal. Além disso, a presente invenção refere-se à utilização da referida composição para o tratamento de rágades anais.
BR112014018850A 2012-01-30 2012-01-30 Composição e sua utilização no tratamento de rágades anais BR112014018850A8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT2012/000027 WO2013114410A1 (en) 2012-01-30 2012-01-30 A composition and use thereof in the treatment of anal rhagades

Publications (2)

Publication Number Publication Date
BR112014018850A2 BR112014018850A2 (pt) 2017-06-20
BR112014018850A8 true BR112014018850A8 (pt) 2017-07-11

Family

ID=46001672

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014018850A BR112014018850A8 (pt) 2012-01-30 2012-01-30 Composição e sua utilização no tratamento de rágades anais

Country Status (24)

Country Link
US (1) US9345747B2 (pt)
EP (1) EP2646039B1 (pt)
JP (1) JP5903505B2 (pt)
KR (1) KR101599447B1 (pt)
CN (2) CN104114177A (pt)
AU (1) AU2012368815B2 (pt)
BR (1) BR112014018850A8 (pt)
CA (1) CA2863369C (pt)
DK (1) DK2646039T3 (pt)
ES (1) ES2485490T3 (pt)
HK (1) HK1186378A1 (pt)
HR (1) HRP20140594T1 (pt)
IL (1) IL233875A (pt)
IN (1) IN2014MN01733A (pt)
MX (1) MX336204B (pt)
PL (1) PL2646039T3 (pt)
RS (1) RS53457B (pt)
RU (1) RU2580622C2 (pt)
SA (1) SA113340239B1 (pt)
SG (1) SG11201404413UA (pt)
SI (1) SI2646039T1 (pt)
TW (1) TWI495476B (pt)
WO (1) WO2013114410A1 (pt)
ZA (1) ZA201405208B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6523291B2 (ja) 2013-12-24 2019-05-29 ザ プロクター アンド ギャンブル カンパニーＴｈｅ Ｐｒｏｃｔｅｒ ＆ Ｇａｍｂｌｅ Ｃｏｍｐａｎｙ スキンケア有効成分の高い浸透性を与える美容組成物及び方法
ITRM20150163A1 (it) * 2015-04-17 2016-10-17 Uniderm Farm S R L Composizioni farmaceutiche per il trattamento delle ragadi anali
US10117826B2 (en) 2016-03-31 2018-11-06 Peter Angia Pham Bodily lubricating and moisturizing compositions containing plant mucilage
US10835504B2 (en) 2018-04-18 2020-11-17 G&S Laboratories, Inc. Compositions to treat anal itch
WO2020022991A2 (en) * 2018-05-02 2020-01-30 Montero Gida Sanayi Ve Ticaret Anonim Sirketi Topical compositions for stretch marks on the skin
RU2771015C2 (ru) * 2020-09-25 2022-04-25 Общество с ограниченной ответственностью "ФАРМКОММ" Фармацевтическая композиция в виде мази для лечения геморроя

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622939A (en) * 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
ATE214266T1 (de) * 1997-04-16 2002-03-15 Cognis France Sa Verwendung einer aus hibiskus-esculentus-samen extrahierten proteinfraktion in der kosmetik
US6379719B1 (en) * 1998-04-08 2002-04-30 Laboratories Serobiologiques (Societe Anonyme) Use of at least one protein fraction extracted from Hibiscus esculentus seeds and cosmetic composition containing such a fraction
CN1233469A (zh) * 1998-04-28 1999-11-03 王京杭 组织修复促进剂
US6956120B2 (en) * 2000-11-09 2005-10-18 Yasushi Onaka β-1.3-1.6 glucan (Aureobasidium medium)
JP2002204687A (ja) * 2000-11-09 2002-07-23 Onaka Yasushi β−１．３−１．６グルカン（アウレオバシジウム培養液）の医療、保健、福祉、食品および各種産業分野での応用
JP2003104832A (ja) * 2001-09-28 2003-04-09 Chifure Keshohin:Kk 皮膚外用剤
JP4544500B2 (ja) 2002-07-19 2010-09-15 一丸ファルコス株式会社 ヒアルロン酸合成促進剤
CA2523021C (en) * 2003-05-02 2013-06-11 Ceapro Inc. Improved extraction and purification method for cereal beta-glucan
RU2277920C2 (ru) * 2004-02-24 2006-06-20 Государственное Учреждение "Пятигорский Государственный Научно-Исследовательский Институт Курортологии Министерства Здравоохранения Российской Федерации" Способ лечения детей, больных хроническим вирусным гепатитом, с применением сульфидных ванн и слабоуглекислой минеральной водой
ITMI20042111A1 (it) * 2004-11-04 2005-02-04 Biofarmitalia Spa Cerotto contenenti una sostanza scelta tra i catrami aventi caratteristiche riducenti in dermatologia
JP5048935B2 (ja) * 2005-08-24 2012-10-17 株式会社ヤクルト本社 保湿剤
DE202007004856U1 (de) * 2007-04-01 2007-06-06 Rühle, Wilfried, Dipl.-Ing. CHM Anti Aging Komplex
CN101095482B (zh) * 2007-07-05 2012-02-15 中国科学院长春应用化学研究所 制备膳食纤维食品用大麦麦麸或燕麦麦麸的制法
US20090202664A1 (en) * 2008-02-11 2009-08-13 Svetislav Mikalacki Herbal cream or oil for the treatment hemorroids and wounds
ITUD20100112A1 (it) * 2010-06-09 2011-12-10 Farma Derma S R L Preparazione per uso vaginale e rettale e relativo procedimento di produzione
CN102084963A (zh) * 2010-09-29 2011-06-08 吉林省农业机械研究院 一种制备燕麦麦麸膳食纤维食品的方法

Also Published As

Publication number Publication date
CN104114177A (zh) 2014-10-22
SA113340239B1 (ar) 2015-07-07
HRP20140594T1 (hr) 2014-10-24
BR112014018850A2 (pt) 2017-06-20
IL233875A0 (en) 2014-09-30
RU2014129391A (ru) 2016-03-27
TWI495476B (zh) 2015-08-11
IL233875A (en) 2017-01-31
DK2646039T3 (da) 2014-08-11
HK1186378A1 (en) 2014-03-14
RS53457B (en) 2014-12-31
AU2012368815B2 (en) 2018-03-01
MX2014009244A (es) 2015-03-19
EP2646039A1 (en) 2013-10-09
MX336204B (es) 2016-01-11
JP2015504915A (ja) 2015-02-16
IN2014MN01733A (pt) 2015-07-10
KR101599447B1 (ko) 2016-03-14
WO2013114410A1 (en) 2013-08-08
US20140303094A1 (en) 2014-10-09
CN109865000A (zh) 2019-06-11
KR20140127296A (ko) 2014-11-03
AU2012368815A1 (en) 2014-09-18
ES2485490T3 (es) 2014-08-13
ZA201405208B (en) 2015-10-28
CA2863369C (en) 2020-03-10
SI2646039T1 (sl) 2014-10-30
RU2580622C2 (ru) 2016-04-10
JP5903505B2 (ja) 2016-04-13
CA2863369A1 (en) 2013-08-08
EP2646039B1 (en) 2014-05-14
US9345747B2 (en) 2016-05-24
PL2646039T3 (pl) 2014-10-31
TW201334787A (zh) 2013-09-01
SG11201404413UA (en) 2014-10-30

Similar Documents

Publication Publication Date Title
BR112018002130A2 (pt) anticorpo de domínio único e proteínas derivadas respectivas contra um ligante de morte programada (pdl1)
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
CO2018000211A2 (es) Moléculas de anticuerpo que se unen a cd45
BR112018000768A2 (pt) anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos
BR112017000664A2 (pt) anticorpo anti-pd-1 e seu uso
BR112016002199B8 (pt) Anticorpo que se liga a um complexo de hgarp e tgf-b1 latente, composição compreendendo o mesmo, uso e linhagem celular de hibridoma
BR112018004532A2 (pt) uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
BR112018009064A8 (pt) anticorpo de pd-l1, fragmento de ligação ao antígeno do mesmo e aplicação médica do mesmo
BR112018001531A2 (pt) construtos de anticorpo para cd70 e cd3
BR112018000475A2 (pt) construtos de anticorpo biespecíficos que se ligam a dll3 e a cd3
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
BR112018001374A2 (pt) construtos de anticorpo biespecíficos que se ligam a egfrviii e cd3
BR112014018850A8 (pt) Composição e sua utilização no tratamento de rágades anais
BR112016013861A2 (pt) conjugados de droga e anticorpo, compostos, método de tratamento e composição farmacêutica
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
BR112019001794A2 (pt) composição de cannabis
CO6670524A2 (es) Proteínas de unión de dominio variable dual que se unen a ngf y al menos a un blanco adicional, y métodos para hacer y usar dichas proteínas de unión
BR112014016808A8 (pt) composições de biguanida e métodos de tratamento de distúrbios metabólicos
CO2017009433A2 (es) Proteínas específicas para pioverdina y pioquelina
BR112016015660A2 (pt) formulação farmacêutica de neuregulina (nrg) e formulação farmacêutica liofilizada de neuregulina (nrg)
AR088083A1 (es) USO DE ANTICUERPOS DE UNION A IL-1b
BR112015030385A8 (pt) composto, composto para uso e composição farmacêutica
BR112014006587A8 (pt) Composto compreendendo oligonucleotídeo que modula a expressão de gcgr, composição, bem como seu uso no tratamento ou prevenção de diabetes
BR112017004056A2 (pt) composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo
BR112015029987A2 (pt) beta-caseína a2 e a prevenção de inflamação do intestino

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2499 DE 27-11-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.